Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;26(7):1100-1106.
doi: 10.1158/1055-9965.EPI-16-1005. Epub 2017 Mar 14.

The Association of the C-Reactive Protein Inflammatory Biomarker with Breast Cancer Incidence and Mortality in the Women's Health Initiative

Affiliations

The Association of the C-Reactive Protein Inflammatory Biomarker with Breast Cancer Incidence and Mortality in the Women's Health Initiative

Sandahl H Nelson et al. Cancer Epidemiol Biomarkers Prev. 2017 Jul.

Abstract

Purpose: To examine associations of prediagnosis high-sensitivity C-reactive protein (hsCRP) with breast cancer incidence and postdiagnosis survival and to assess whether associations are modified by body mass index (BMI).Methods: A prospective analysis of the Women's Health Initiative was conducted among 17,841 cancer-free postmenopausal women with baseline hsCRP measurements. Cox proportional hazards models were used to examine associations between hsCRP concentrations and (i) breast cancer risk (n cases = 1,114) and (ii) all-cause mortality after breast cancer diagnosis. HRs are per 1 SD in log hsCRP.Results: hsCRP was not associated with breast cancer risk overall [HR = 1.05; 95% confidence interval (CI), 0.98-1.12]; however, an interaction between BMI and hsCRP was observed (Pinteraction = 0.02). A 1 SD increase in log hsCRP was associated with 17% increased breast cancer risk (HR = 1.17; 95% CI, 1.03-1.33) among lean women (BMI < 25), whereas no association was observed among overweight/obese (BMI ≥ 25) women. Prediagnosis hsCRP was not associated with overall mortality (HR, 1.04; 95% CI, 0.88-1.21) after breast cancer diagnosis; however, an increased mortality risk was apparent among leaner women with higher hsCRP levels (HR, 1.39, 95% CI, 1.03-1.88).Conclusions: Prediagnosis hsCRP levels are not associated with postmenopausal breast cancer incidence or survival overall; however, increased risks are suggested among leaner women. The observed effect modification is in the opposite direction of a previous case-control study finding and warrants further investigation.Impact: Associations of higher CRP levels with incident breast cancer and survival after breast cancer may depend on BMI. Cancer Epidemiol Biomarkers Prev; 26(7); 1100-6. ©2017 AACR.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow-chart for analytic sample
Figure 2
Figure 2
Incident Breast Cancer Hazard Ratios and 95% CIs in the WHI Biospecimen Cohort, Per 1 SD Natural Log Unit of hsCRP, Overall and by BMI Level (n=17,841) Abbreviations: High Sensitivity C-Reactive Protein (CRP), Body Mass Index (BMI), Standard deviation (SD), Hazard Ration (HR), Lower and Upper level of 95% confidence interval (LL and UL)
Figure 3
Figure 3
All Cause Mortality Among Incident Breast Cancer Cases. Hazard Ratios and 95% CIs in the WHI Biospecimen Cohort, Per 1 SD Natural Log Unit of hsCRP, Overall and by BMI Level (n=1,114) Abbreviations: High Sensitivity C-Reactive Protein (CRP), Body Mass Index (BMI), Standard deviation (SD), Hazard Ration (HR), Lower and Upper level of 95% confidence interval (LL and UL)

References

    1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001 Feb 17;357(9255):539–45. - PubMed
    1. Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007 Sep;61(9):824–33. - PMC - PubMed
    1. Guo L, Liu S, Zhang S, Chen Q, Zhang M, Quan P, et al. C-reactive protein and risk of breast cancer: A systematic review and meta-analysis. Sci Rep. 2015;5:10508. - PMC - PubMed
    1. Chan DS, Bandera EV, Greenwood DC, Norat T. Circulating C-Reactive Protein and Breast Cancer Risk-Systematic Literature Review and Meta-analysis of Prospective Cohort Studies. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2015 Oct;24(10):1439–49. - PubMed
    1. Dossus L, Jimenez-Corona A, Romieu I, Boutron-Ruault MC, Boutten A, Dupre T, et al. C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study. Cancer Causes Control. 2014 Apr;25(4):533–9. - PubMed

Publication types